This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ACHN Achillion Pharmaceuticals (ACHN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Achillion Pharmaceuticals Stock (NASDAQ:ACHN) 30 days 90 days 365 days Advanced Chart Get ACHN alerts:Sign Up Key Stats Today's Range$6.76▼$6.7650-Day Range$6.76▼$6.7652-Week Range$2.06▼$7.01VolumeN/AAverage Volume8.44 million shsMarket Capitalization$946.72 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut. Read More Receive ACHN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACHN Stock News HeadlinesKim P. Kamdar's Net WorthMarch 30, 2024 | benzinga.comLexicon Pharmaceuticals (NASDAQ: LXRX)May 20, 2023 | fool.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 28 at 2:00 AM | American Alternative (Ad)Gilead Sciences Buying Achillion Was Twitter Speculation at Its FinestFebruary 19, 2023 | thestreet.comACHN_old Historical DataSeptember 18, 2022 | investing.comWhy Achillion Pharmaceuticals (ACHN) Stock Is Up in After-Hours Trading TodayJanuary 13, 2022 | thestreet.comJim Cramer's 'Mad Money' Recap: Here's Next Week's Game PlanJanuary 12, 2022 | thestreet.comSee More Headlines ACHN Stock Analysis - Frequently Asked Questions How were Achillion Pharmaceuticals' earnings last quarter? Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its earnings results on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. What other stocks do shareholders of Achillion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NEBLQ), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR) and Meta Platforms (META). Company Calendar Last Earnings11/07/2019Today8/28/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ACHN CIK1070336 Webwww.achillion.com Phone203-624-7000FaxN/AEmployees56Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.95% Return on Assets-29.09% Debt Debt-to-Equity Ratio0.01 Current Ratio8.96 Quick Ratio8.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.92 per share Price / Book3.52Miscellaneous Outstanding Shares140,047,000Free FloatN/AMarket Cap$946.72 million OptionableOptionable Beta1.59 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ACHN) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump's "Big Beautiful Bill" hides ugly truthWashington’s new “Big Beautiful Bill” promises tax breaks… but the fine print tells a different story: trillio...Defi Master | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achillion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achillion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.